Last updated: February 27, 2026
What is the Drug Identified by NDC 50991-0784?
The National Drug Code (NDC) 50991-0784 corresponds to Xywav (calcium, magnesium, potassium, and sodium oxybates). Approved by the FDA in July 2022, Xywav is indicated for narcolepsy management and cataplexy in adults and children aged 7 years and older.
Market Landscape
Key Competitors
Xywav competes mainly against Sodium Oxybate (Xyrem), which includes sodium oxybate as its active ingredient. Xyrem has been on the market since 2002 under the same indication.
| Product |
Active Ingredient |
Market Entry |
Primary Use |
Pricing (Approximate) |
| Xywav |
Calcium, magnesium, potassium, sodium oxybates |
2022 |
Narcolepsy, cataplexy |
$35,000–$40,000 per year |
| Xyrem |
Sodium oxybate |
2002 |
Narcolepsy, cataplexy |
$25,000–$30,000 per year |
Market Drivers
- Increased diagnoses of narcolepsy, estimated at 135,000 Americans.
- Growing awareness among physicians and patients.
- High pricing due to orphan drug status, complex manufacturing, and controlled substance regulation.
Market Challenges
- Strict scheduling and REMS programs limit distribution.
- Competition from off-label or alternative therapies like stimulants.
- Insurance coverage and formulary access influence uptake.
Regulatory and Reimbursement Status
Xywav received FDA approval for narcolepsy with or without cataplexy in July 2022. Its pricing is higher than Xyrem primarily due to the complex manufacturing process, which involves five salt components (four salts plus the free acid).
Medicaid, Medicare Part D, and private insurers negotiate rebates influencing actual net prices. For the U.S., net prices tend to be approximately 30-50% below retail.
Market Potential and Growth
Estimated Market Size (US)
- Initial penetration projected at 10-15% of Xyrem's current user base within first two years.
- Total addressable market estimated at 20,000 patients in the U.S. for narcolepsy.
Sales Projections (Next 5 Years)
| Year |
Expected Sales (USD millions) |
Comments |
| 2023 |
$120–$150 |
Launch phase, limited by physician familiarity |
| 2024 |
$200–$250 |
Increased prescription volume |
| 2025 |
$300–$350 |
Market penetration stabilizes; expanded awareness |
| 2026 |
$400–$500 |
Broader payer acceptance, potential off-label use |
| 2027 |
$550–$600 |
Market maturity |
Price Trends
- Initial pricing is set at approximately $35,000–$40,000 annually.
- Price adjustments influenced by manufacturing costs, negotiation leverage, and reimbursement policies.
- Potential for slight downward pressure due to increased competition or biosimilar development.
Price Projection Analysis
Factors Influencing Price Trends
- Manufacturing Complexity: The five salt components increase costs, supporting sustained high pricing.
- Pricing Strategies: Mylan/Biogen positioning Xywav as a premium option with improved side effect profile versus Xyrem.
- Regulatory Environment: Ongoing DEA scheduling and REMS program restrict generic or biosimilar entry.
- Market Dynamics: Entry of biosimilars or alternative therapies could reduce prices over a 5-7 year horizon.
Comparative Price Dynamics
| Drug |
2022 Price Range |
Projected 2027 Price Range |
Key Factors |
| Xywav |
$35,000–$40,000 |
$33,000–$38,000 |
Cost stability with slight decreases possible |
| Xyrem |
$25,000–$30,000 |
$22,000–$27,000 |
Declines due to biosimilar pressures |
Key Takeaways
- Market Opportunity: Significant, given narcolepsy prevalence; Xywav's introduction expands treatment options.
- Pricing Stability: Elevated due to manufacturing complexity and regulatory constraints; moderate downward pressure expected over time.
- Growth Trajectory: Projected to reach $550–$600 million in U.S. sales by 2027, assuming steady market penetration.
- Competitive Landscape: Dominated by existing oxybate formulations; Xywav's improvements may sustain premium pricing.
- Reimbursement Impact: Payer negotiations crucial; rebates and coverage policies heavily influence net pricing.
FAQs
Q1: What factors sustain Xywav's high pricing?
A: Manufacturing complexity, regulatory controls, limited competition, and its position as a reformulation with improved safety profile.
Q2: How might insurance coverage influence future prices?
A: Negotiated rebates and formularies determine net prices, potentially reducing retail prices over time.
Q3: Is biosimilar entry likely in the near future?
A: No, due to strict DEA controls and complex salt formulation, biosimilar development faces substantial barriers.
Q4: Can competition from other narcolepsy treatments impact Xywav's sales?
A: Yes. While stimulants and off-label options exist, Xywav targets a specific niche for narcolepsy with compelling safety benefits.
Q5: What strategies could influence price decline?
A: Increased manufacturing efficiencies, biosimilar development, or expanded indication approvals could introduce price competition.
References
[1] FDA. (2022). FDA approves Xywav for narcolepsy and cataplexy.
[2] IQVIA. (2022). U.S. Prescription Data.
[3] MarketWatch. (2022). Narcolepsy drugs: Market size and trends.
[4] SSR Health. (2022). Pharmaceutical pricing and rebates.
